GlassScriptPhysician profile
Xianwen Qiao
NPI 1285972885
$11,395.17
in general payments reported to CMS, 2019-2025
49 companies · $2,167 in 2025
The $2,167 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,877 · 2022: $1,800 · 2023: $2,486 · 2024: $3,065 · 2025: $2,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,718.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,738.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $962.98 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $734.11 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $680.00 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $597.91 | 2021-2024 | Xarelto |
| Phathom Pharmaceuticals, INC. | $538.75 | 2024-2025 | Voquezna |
| Abbott Laboratories | $472.23 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Daiichi Sankyo INC. | $378.27 | 2021-2025 | Injectafer |
| Pfizer INC. | $327.12 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.40 | 2021-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Astellas Pharma US INC | $274.24 | 2021-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $245.64 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $238.20 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $229.93 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $228.86 | 2021-2024 | Repatha, Otezla, Evenity |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $219.95 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Amarin Pharma, INC. | $208.11 | 2021 | |
| Alkermes, INC. | $179.12 | 2022-2025 | Vivitrol, Vivitrol |
| Lundbeck LLC | $175.24 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $169.92 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $128.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.20 | 2021-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $93.25 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $90.17 | 2021-2024 | Capvaxive, Gardasil 9, Pneumovax 23 |
| Nestle Healthcare Nutrition INC. | $82.79 | 2022-2023 | |
| Axsome Therapeutics, INC. | $82.31 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $72.01 | 2021-2022 | |
| Vivus LLC | $69.02 | 2025 | Qsymia |
| Verona Pharma, INC. | $64.10 | 2025 | Ohtuvayre |
| Vanda Pharmaceuticals INC. | $62.18 | 2025 | Fanapt |
| Electromed, INC. | $59.44 | 2024-2025 | Smartvest |
| Biohaven Pharmaceutical Holding Company LTD. | $58.84 | 2022 | |
| Ucb, INC. | $52.58 | 2022 | |
| Sanofi-Aventis U.S. LLC | $50.69 | 2021 | |
| Gilead Sciences, INC. | $45.82 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.18 | 2023 | |
| Antares Pharma, INC. | $41.32 | 2024-2025 | Xyosted |
| Otsuka America Pharmaceutical, INC. | $41.27 | 2023-2025 | Nuedexta, Rexulti |
| Kiniksa Pharmaceuticals, LTD. | $34.88 | 2023 | Arcalyst |
| Shield Therapeutics INC | $32.02 | 2023-2024 | Accrufer |
| Medtronic, INC. | $29.76 | 2025 | Inceptiv |
| Biogen, INC. | $29.52 | 2021-2025 | Spinraza |
| Kowa Pharmaceuticals America, INC. | $24.27 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $23.23 | 2024 | Arcalyst |
| Sunovion Pharmaceuticals INC. | $22.74 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.03 | 2023 | Quviviq |
| Seqirus USA INC | $18.88 | 2025 | Flucelvax, Fluad |
| Indivior INC. | $18.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xianwen Qiao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.